Li, J., Xu, T., Zhang, W., Li, W., Kang, Z., Yuan, Z., Jiang, W., Li, X., Zhang, Y., Kang, D., Wang, Y., Xia, B., Zhang, J., Xu, Y., Wu, S., Shen, L. (2025). A phase 1, multicenter, open-label study of HSK42360, a brain-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3109